(Press-News.org) The drug reboxetine is, overall, an ineffective and potentially harmful antidepressant, according to a comprehensive study of the evidence published on bmj.com today.
The study also shows that nearly three quarters of the data on patients who took part in trials of reboxetine were not published until now, and that the published data on the drug overestimate the benefits and underestimate the harms of treatment - all underlining the urgent need for mandatory publication of all clinical trial results.
Reboxetine has been approved for the treatment of major depressive disorder in many European countries since 1997, but doubts have been raised about its effectiveness on the basis of recent studies and rejection of the application for approval in the United States in 2001. Published trials, however, show a favourable risk-benefit profile for reboxetine.
So a team of researchers at The German Institute for Quality and Efficiency in Health Care (IQWiG) set out to assess the benefits and harms of reboxetine compared with placebo or other antidepressants, known as selective serotonin reuptake inhibitors (SSRIs), for treating adults with major depression.
They also measured the impact of potential publication bias in trials of reboxetine (where positive trial results are more likely to be published than unfavourable results).
They analysed the results of 13 trials, including eight previously unpublished trials from the manufacturer of reboxetine (Pfizer). The overall quality of the trials was good, but the researchers noted that data on 74% of patients were unpublished.
They show that reboxetine is, overall, an ineffective and potentially harmful antidepressant. They found no significant difference in benefit (remission and response rates) versus placebo and inferior benefit versus SSRIs, as well as a higher rate of patients affected by adverse events than with placebo and higher withdrawal rates owing to adverse events than with placebo and the SSRI fluoxetine.
A further comparison of published and unpublished trials shows that published data overestimated the benefit of reboxetine and underestimated harm.
This, say the authors, is a striking example of publication bias, resulting in a distorted public record of a treatment. Publication bias can affect health policy decisions and the content of clinical guidelines, they warn. "Our findings underline the urgent need for mandatory publication of trial data."
In an accompanying analysis, the same authors argue that current regulations on the publication of trial results are insufficient. They believe several measures are required in order to provide patients, clinicians, and health policy makers with unbiased and verified evidence on which to base decisions.
These include mandatory public disclosure of data for all drugs, even for those never approved, public access to trials of older drugs not covered by current law, greater data sharing between regulatory authorities, as well as re-evaluation of a drug if approval is declined elsewhere, and a legal obligation for manufacturers to provide all requested data to official bodies without restrictions to publication.
In a second analysis, senior researchers Robert Steinbrook and Jerome Kassirer highlight several recent examples that illustrate the problems of trusting drug companies to provide the complete picture about the clinical trials they sponsor. They propose that journals should define full access to all the trial data and require that investigators and journal editors have full access. Editors should also take appropriate action if concerns about data arise after publication. "Trust in the medical literature, not just in industry sponsored trials, is at stake," they conclude.
In an accompanying editorial, BMJ Editors Dr Fiona Godlee and Dr Elizabeth Loder, argue that "the medical evidence base is distorted by missing clinical trial data" and that "urgent action is needed to restore trust in existing evidence."
They believe it is important to re-evaluate the integrity of the existing base of research evidence and, as such, the BMJ will devote a special theme issue to this topic in late 2011.
"Full information about previously conducted clinical trials involving drugs, devices and other treatments is vital to clinical decision-making," they say. "It is time to demonstrate a shared commitment to set the record straight."
INFORMATION: END
To assess the performance of general practices, it is better to ask patients about their actual experiences of care rather than ask for satisfaction ratings, according to new research published on bmj.com today.
The findings call into question the reliability of using surveys to evaluate practice performance.
Patient surveys are used to assess the performance of doctors and practices, and they increasingly enquire about specific patient experiences (e.g. waiting time for an appointment) as well as overall satisfaction.
In the UK, general practices receive some of ...
In a Canadian first, the Peter Munk Cardiac Centre used a new kind of left ventricular assist device (LVAD) to treat a patient with advanced heart failure. The new device is longer lasting than older generation LVADs and may eliminate the need for a second LVAD – a major drawback with the old technology.
The patient, 61-year-old Marva Lorde of Mississauga, suffered a heart attack in 2007 and underwent several treatments for heart failure – including a 10-day intensive care unit stay, angioplasty and pacemaker implantation –culminating in a cardiac arrest in June 2008.
"I ...
With Halloween and the holiday season fast approaching, many people will be watching their waistlines as they're tempted by a cornucopia of sugary and savory foods. Meanwhile a Georgia Tech College of Computing Ph.D. candidate has shown that playing health-related video games on a mobile device can help adults learn to live more healthfully by making smart diet choices. The finding is published in the paper, "Let's Play! Mobile Health Games for Adults," recently presented at Ubicomp 2010 in Copenhagen, Denmark.
OrderUP! is a different take on the recent trend of health-related ...
An innovative experiment at the University of Leicester that involved studying rotting fish has helped to create a clearer picture of what our early ancestors would have looked like.
The scientists wanted to examine the decaying process in order to understand the decomposition of soft-body parts in fish. This in turn will help them reconstruct an image of creatures that existed 500 million years ago.
Their findings have been published today, Wednesday 13th October, in the journal Proceedings of the Royal Society B. The work was funded by the Natural Environment Research ...
Eating steamed pears, having a soothing massage or bathing in a herbal mixture are just some of indigenous health practices used by older people to ward off or treat influenza, according to research published in the October issue of the Journal of Advanced Nursing.
Other traditional measures discovered by nurse researchers at the Hong Kong Polytechnic University included being rubbed with a coin, eating cheese, yoghurt and honey and having warm drinks made with ginger or lemon.
The team surveyed nine countries to find out why so many of them were failing to meet the ...
Winter canola might soon be the crop of choice for Pacific Northwest farmers, thanks to research by U.S. Department of Agriculture (USDA) scientists and their partners. The multitasking annual plant can be used to control weeds, supplement animal feed, produce biodiesel--and spark a new revenue stream for the Colville Confederated Tribes.
Frank Young, an agronomist with USDA's Agricultural Research Service (ARS), was part of a team that evaluated production protocols for winter canola in the Pacific Northwest. ARS is USDA's principal intramural scientific research agency. ...
Scientists at the University of Leicester are using an unusual resource to investigate ancient climates– prehistoric animal urine.
The animal in question is the rock hyrax, a common species in countries such as Namibia and Botswana. They look like large guinea pigs but are actually related to the elephant. Hyraxes use specific locations as communal toilets, some of which have been used by generations of animals for thousands of years. The urine crystallises and builds up in stratified accumulations known as 'middens', providing a previously untapped resource for studying ...
Scientists at the UK's National Physical Laboratory (NPL) have developed a means of representing a 3D model ear, to help redefine the standard for a pinna simulator (the pinna is the outer part of the ear) – used to measure sound in the way we perceive it.
The nature of human hearing is heavily dependent on the shape of the head and torso, and their interaction with sound reaching the ears allows for the perception of location within a 3D sound field.
Head and Torso Simulators (HATS) are designed to model this behaviour, enabling measurements and recordings to be made ...
The metal chromium is an essential nutrient for plant and animal metabolism, but it can accumulate to toxic and hazardous levels in the environment when discharged in industrial waste water; a point made infamous by the movie Erin Brockovich.
Chromium-contaminated wastewaters usually originate from dye and pigment manufacturing, wood preserving, electroplating and leather tanning. The element can exist in water as charged particles in one of two states, oxidation state 3+ (trivalent form) and 6+ (the hexavalent form usually exists as chromate or dichromate). Other oxidation ...
Having a family history of breast cancer can lead some women to wonder if the risk is out of their control. However, a study of more than 85,000 postmenopausal women, published in BioMed Central's open access journal Breast Cancer Research, observed that regular physical activity, maintaining a healthy weight, and drinking less alcohol lowers breast cancer risk for those with and without a family history of the disease.
The University of Rochester Medical Center study is good news for women who have a close relative with breast cancer and fear that no matter what they ...
